Trial Profile
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs Midazolam (Primary) ; Midazolam (Primary)
- Indications Status epilepticus
- Focus Registrational; Therapeutic Use
- Sponsors Shire; Takeda
- 17 Feb 2020 Status changed from recruiting to completed.
- 20 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 New trial record